Is aminoglycoside-associated nephrotoxicity uncommon in the U.K?
Fifty adult patients who were treated with aminoglycosides (AG) were studied prospectively. All patients were assessed by the investigators for AG-associated nephrotoxicity using criteria as defined by each prescriber, compared to a standard published set of criteria. The prescribers stated that none of the patients suffered toxicity using their criteria. Thirteen patients (26%) suffered toxicity using the published criteria. No patients were dosed on a pharmacokinetic basis. All patients with toxicity had trough levels greater than 2.0 mg/l, and those six patients with severe toxicity also had peak levels greater than 10.0 mg/l. It is suggested that prescribers in the U.K. may not be as familiar or concerned with AG dosing methods and nephrotoxicity as their U.S. counterparts.
University of Manchester Department of Pharmacy, Hope Hospital, Salford, U.K.
G R
GR
Bailie
A
A
Mathews
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000097:blood; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D006113:United Kingdom
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents